Shandong Keyuan Pharmaceutical Co (SZSE:301281) EBIT: ¥25.9 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301281 Shandong Keyuan Pharmaceutical Co Ltd SZSE:301281
67 GF Score
Price ¥46.62
GF Value ¥30.42
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Shandong Keyuan Pharmaceutical Co EBIT?

Shandong Keyuan Pharmaceutical Co SZSE:301281 -7.54% 67 EBIT is ¥25.9 Mil as of Mar. 2026. GuruFocus rates SZSE:301281 with a GF Score™ of 67/100 and a GF Value™ of ¥30.42 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Shandong Keyuan Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥32.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥25.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shandong Keyuan Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 was 11.23%. Shandong Keyuan Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 16.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shandong Keyuan Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.53%.

Shandong Keyuan Pharmaceutical Co  (SZSE:301281) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shandong Keyuan Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=144.904 * ( 1 - 6.6% )/( (1167.457 + 1243.445)/ 2 )
=135.340336/1205.451
=11.23 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1687.665 - 161.13 - ( 359.078 - max(0, 175.987 - 652.391+359.078))
=1167.457

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1790.796 - 183.746 - ( 363.605 - max(0, 239.675 - 731.573+363.605))
=1243.445

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shandong Keyuan Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=131.008/( ( (679.364 + max(83.124, 0)) + (683.331 + max(131.067, 0)) )/ 2 )
=131.008/( ( 762.488 + 814.398 )/ 2 )
=131.008/788.443
=16.62 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(96.092 + 147.447 + 15.572) - (161.13 + 0 + 14.857)
=83.124

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(174.818 + 141.478 + 15.011) - (183.746 + 0 + 16.494)
=131.067

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shandong Keyuan Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=25.898/4842.551
=0.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Keyuan Pharmaceutical Co EBIT Related Terms

Shandong Keyuan Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Shandong Keyuan Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Keyuan Pharmaceutical Co EBIT Chart

Shandong Keyuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.14 98.62 65.67 65.75 16.80

Shandong Keyuan Pharmaceutical Co Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.65 20.13 -11.82 -15.17 32.75

SZSE:301281 vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Shandong Keyuan Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shandong Keyuan Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Keyuan Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shandong Keyuan Pharmaceutical Co's EV-to-EBIT falls into.


SZSE:301281
67GF Score
Shandong Keyuan Pharmaceutical Co Ltd SZSE:301281
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Keyuan Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥25.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥25.9 Mil mean?
Shandong Keyuan Pharmaceutical Co (SZSE:301281) has a EBIT of ¥25.9 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Keyuan Pharmaceutical Co.
Is Shandong Keyuan Pharmaceutical Co's EBIT too high?
Shandong Keyuan Pharmaceutical Co's current EBIT is ¥25.9 Mil. Overall, Shandong Keyuan Pharmaceutical Co has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Keyuan Pharmaceutical Co's EBIT compare to LLY and JNJ?
Shandong Keyuan Pharmaceutical Co's EBIT of ¥25.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shandong Keyuan Pharmaceutical Co. Shandong Keyuan Pharmaceutical Co's current EBIT is ¥25.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Keyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co (SZSE:301281) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥30.42, compared to a current price of ¥46.62 — trading 53.3% above its estimated fair value. The current EBIT is ¥25.9 Mil. Shandong Keyuan Pharmaceutical Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shandong Keyuan Pharmaceutical Co (SZSE:301281), the current EBIT is ¥25.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Keyuan Pharmaceutical Co (SZSE:301281) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥46.62 is trading 53.3% above its estimated GF Value™ of ¥30.42. GuruFocus considers Shandong Keyuan Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SZSE:301281:

  • EBIT: ¥25.9 Mil
  • GF Value™: ¥30.42 vs. price of ¥46.62 (53.3% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SZSE:301281 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Keyuan Pharmaceutical Co Business Description

Address Keyuan Street, Shandong Shanghe Economic Development Zone, Shandong Province, Jinan, CHN, 251601
Shandong Keyuan Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of chemical raw materials and their preparations.
67GF Score

Get the complete analysis for SZSE:301281

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥46.62
Price
¥30.42
GF Value